1 - 25 of 2
Number of results to display per page
TitleCreatorDescriptionIdentifier
1 Efficacy and Safety of Satralizumab from Two Phase 3 Trials in Neuromyelitis Optica Spectrum Disorder (Slides)Benjamin Frishberg, Jerome de Seze, Brian Weinshenker, Yusuke Terada, Yuichi Kawata, Athos Gianella-Borradori, H. Christianvon Büdingen, Gaelle Klingelschmitt, Anthony Traboulsee, Takashi YamamuraSatralizumab is a humanized recycling monoclonal antibody that binds to the interleukin-6 (IL-6) receptor; IL-6 has been implicated in the pathophysiology of neuromyelitis optica spectrum disorder (NMOSD). Satralizumab was evaluated in patients with NMOSD in two Phase 3 studies: SAkuraSky (NCT020288...20200309_nanos_sciplatform1_03-slides
2 Efficacy and Safety of Satralizumab from Two Phase 3 Trials in Neuromyelitis Optica Spectrum Disorder (PDF)Benjamin Frishberg, Jerome de Seze, Brian Weinshenker, Yusuke Terada, Yuichi Kawata, Athos Gianella-Borradori, H. Christianvon Büdingen, Gaelle Klingelschmitt, Anthony Traboulsee, Takashi YamamuraSatralizumab is a humanized recycling monoclonal antibody that binds to the interleukin-6 (IL-6) receptor; IL-6 has been implicated in the pathophysiology of neuromyelitis optica spectrum disorder (NMOSD). Satralizumab was evaluated in patients with NMOSD in two Phase 3 studies: SAkuraSky (NCT020288...20200309_nanos_sciplatform1_03-pdf
1 - 25 of 2